Genomtec S.A. (GMT) - Total Liabilities
Based on the latest financial reports, Genomtec S.A. (GMT) has total liabilities worth zł6.01 Million PLN (≈ $1.65 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Genomtec S.A. (GMT) net asset momentum to track the company's year-over-year net asset growth rate.
Genomtec S.A. - Total Liabilities Trend (2019–2024)
This chart illustrates how Genomtec S.A.'s total liabilities have evolved over time, based on quarterly financial data. See Genomtec S.A. (GMT) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Genomtec S.A. Competitors by Total Liabilities
The table below lists competitors of Genomtec S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Delta Resources Ltd
V:DLTA
|
Canada | CA$743.51K |
|
Sycal Ventures Bhd
KLSE:9717
|
Malaysia | RM184.79 Million |
|
Czerwona Torebka
WAR:CZT
|
Poland | zł188.96 Million |
|
SYZYGY AG
XETRA:SYZ
|
Germany | €29.33 Million |
|
Almadex Minerals Ltd
V:DEX
|
Canada | CA$342.64K |
|
Apimeds Pharmaceuticals US, Inc.
NYSE MKT:APUS
|
USA | $1.09 Million |
|
RNI Negócios Imobiliários S.A
SA:RDNI3
|
Brazil | R$987.10 Million |
|
Australian Rare EARTHS Ltd
AU:AR3
|
Australia | AU$2.17 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Genomtec S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Genomtec S.A..
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genomtec S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genomtec S.A. (2019–2024)
The table below shows the annual total liabilities of Genomtec S.A. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | zł9.44 Million ≈ $2.60 Million |
+23.09% |
| 2023-12-31 | zł7.67 Million ≈ $2.11 Million |
+11.68% |
| 2022-12-31 | zł6.87 Million ≈ $1.89 Million |
+97.47% |
| 2021-12-31 | zł3.48 Million ≈ $957.20K |
+93.33% |
| 2020-12-31 | zł1.80 Million ≈ $495.11K |
-0.13% |
| 2019-12-31 | zł1.80 Million ≈ $495.77K |
-- |
About Genomtec S.A.
Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company's flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysi… Read more